Description: <p><b>Docosahexaenoic Acid (DHA)</b> = long-chain omega-3 polyunsaturated fatty acid (22:6n-3); major structural lipid of neuronal membranes and retina; dietary sources: fatty fish (salmon, sardine), algae oils; often combined with EPA in supplements.<br>
<b>Primary mechanisms (conceptual rank):</b><br>
1) Membrane incorporation → alters fluidity, lipid rafts, receptor signaling domains.<br>
2) Pro-resolving lipid mediator precursor (resolvins, protectins, maresins) → inflammation resolution.<br>
3) Mitochondrial modulation → can ↑ lipid-ROS in cancer (pro-ferroptotic bias) yet stabilize neuronal bioenergetics.<br>
4) Synaptic function / neurogenesis support (BDNF-linked, model-dependent).<br>
<b>PK / bioavailability:</b> absorbed with dietary fat; re-esterified into phospholipids; crosses BBB; brain incorporation is gradual (weeks–months); higher RBC-DHA correlates with intake.<br>
<b>In-vitro vs systemic exposure:</b> many cancer studies use ≥25–100 µM free DHA; achievable plasma levels from oral dosing are typically lower and largely esterified, limiting direct comparability.<br>
<b>Clinical evidence status:</b> strong cardiometabolic data; oncology evidence largely preclinical/adjunct; AD/MCI data mixed but mechanistically coherent.</p>
<b>Omega-3 fatty acid</b> found in cold-water fish and some supplements.<br>
– DHA is a major structural component of cell membranes in the brain, retina, and other tissues and plays a critical role in neural function and development.<br>
<br>
Role in Cancer<br>
<br>
Anti-Inflammatory Effects: – A reduction in chronic inflammation<br>
Modulation of Cell Proliferation and Apoptosis<br>
–Omega-3 fatty acids appear to influence cell cycle regulation and apoptosis (programmed cell death). By enhancing apoptosis and inhibiting proliferation, these agents may limit the growth of cancer cells.<br>
Alteration of Membrane Composition and Signaling<br>
–May affect processes such as angiogenesis (formation of new blood vessels), cell adhesion, and metastasis in cancer cells.<br>
Impact on Oxidative Stress<br>
–Although omega-3 fatty acids are prone to oxidation, their metabolites can have antioxidant properties. Balancing oxidation and antioxidant defenses is important in preventing oxidative stress—a known contributor to DNA damage and cancer development.<br>
Anti-Angiogenic Effects<br>
– Some studies have shown that EPA and DHA can inhibit angiogenesis.<br>
<br>
<h3>DHA Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Membrane phospholipid enrichment and lipid rafts</td>
<td>Oncogenic receptor clustering ↓<br>Membrane DHA ↑</td>
<td>Membrane fluidity and physiological signaling ↔ or ↑</td>
<td>G</td>
<td>Reorganizes membrane-dependent signaling</td>
<td>DHA gradually replaces other membrane fatty acids and can alter EGFR, PI3K/Akt, ERK, transporters, adhesion molecules, and lipid-raft organization (context-dependent).</td>
</tr>
<tr>
<td>2</td>
<td>Phospholipid peroxidation and ferroptosis</td>
<td>Lipid ROS ↑<br>Ferroptosis ↑</td>
<td>Lipid peroxidation ↔ or ↑ (dose-dependent)</td>
<td>P R</td>
<td>Creates an oxidizable membrane substrate</td>
<td>Six double bonds make DHA highly susceptible to peroxidation. Sensitivity is greatest when GPX4, glutathione, FSP1, or other lipid-peroxide defenses are inadequate. Strong direct effects generally require free DHA or prior membrane enrichment.</td>
</tr>
<tr>
<td>3</td>
<td>GPX4 glutathione ferroptosis defense</td>
<td>Dependence on GPX4 ↑<br>Resistance when NRF2 or GPX4 ↑</td>
<td>Antioxidant buffering ↑</td>
<td>R G</td>
<td>Determines selectivity of DHA-induced lipid damage</td>
<td>DHA does not consistently inhibit GPX4 directly. It increases the burden of peroxidizable phospholipid, thereby exposing differential antioxidant capacity between cells.</td>
</tr>
<tr>
<td>4</td>
<td>PI3K Akt survival signaling</td>
<td>Akt phosphorylation ↓<br>Survival signaling ↓</td>
<td>↔ (context-dependent)</td>
<td>R G</td>
<td>Promotes apoptosis and reduces growth signaling</td>
<td>Reported in prostate, breast, and other experimental models; effects may result partly from altered membrane microdomains and receptor localization.</td>
</tr>
<tr>
<td>5</td>
<td>Wnt beta-catenin and epithelial plasticity</td>
<td>β-catenin signaling ↓<br>EMT ↓<br>Migration ↓</td>
<td>↔</td>
<td>G</td>
<td>Suppresses invasive and stem-like phenotypes</td>
<td>Evidence is primarily cell and animal based. The response varies with tumor genotype, DHA formulation, concentration, and duration.</td>
</tr>
<tr>
<td>6</td>
<td>Mitochondrial bioenergetics</td>
<td>OCR ↓<br>ATP ↓<br>Mitochondrial stress ↑</td>
<td>Membrane function ↔ or ↑</td>
<td>R G</td>
<td>Restricts cancer-cell metabolic capacity</td>
<td>DHA may alter mitochondrial phospholipids, electron transport, membrane potential, and susceptibility to oxidant injury. Direction in normal tissues depends on nutritional state and disease model.</td>
</tr>
<tr>
<td>7</td>
<td>Glycolysis and lipogenic metabolism</td>
<td>Glucose uptake ↓<br>ECAR ↓<br>Lactate production ↓<br>FASN ↓</td>
<td>↔</td>
<td>G</td>
<td>Attenuates the Warburg phenotype</td>
<td>Metabolic inhibition has been demonstrated in selected breast-cancer models but is not established as a universal DHA response.</td>
</tr>
<tr>
<td>8</td>
<td>Inflammatory resolution and NF-kB</td>
<td>NF-κB ↓<br>COX-2 ↓<br>Inflammatory signaling ↓</td>
<td>Resolution programs ↑</td>
<td>R G</td>
<td>Reduces tumor-promoting inflammatory tone</td>
<td>Includes direct membrane effects and conversion to resolvins, protectins, and maresins. Formation of individual mediators depends on enzyme expression and local inflammatory context.</td>
</tr>
<tr>
<td>9</td>
<td>HIF-1 alpha and hypoxic adaptation</td>
<td>HIF-1α ↓<br>GLUT1 ↓</td>
<td>↔</td>
<td>G</td>
<td>Restricts adaptation to hypoxia</td>
<td>Observed in selected tumor models and may be secondary to altered metabolism or signaling rather than a direct DHA target.</td>
</tr>
<tr>
<td>10</td>
<td>Antitumor immunity and PD-L1</td>
<td>PD-L1 ↓ (model-dependent)<br>Immune evasion ↓</td>
<td>Immune-cell phenotype modulated</td>
<td>G</td>
<td>May improve immune recognition</td>
<td>Preclinical evidence includes enhanced proteasomal degradation of PD-L1. Recent human adjunct studies show immune and oxylipin changes but do not yet establish improved cancer outcomes.</td>
</tr>
<tr>
<td>11</td>
<td>NRF2 antioxidant adaptation</td>
<td>NRF2 ↑ or ↔ (secondary)<br>Ferroptosis resistance ↑ when activated</td>
<td>NRF2 ↑ (protective)</td>
<td>R G</td>
<td>Buffers DHA-derived oxidative stress</td>
<td>NRF2 is not a uniformly suppressed DHA target. Secondary NRF2 activation can protect normal cells but may also permit tumor resistance to lipid peroxidation.</td>
</tr>
<tr>
<td>12</td>
<td>Calcium and endoplasmic reticulum stress</td>
<td>Ca²⁺ dysregulation ↑<br>ER stress ↑<br>Apoptosis ↑</td>
<td>↔ or stress ↑ (high concentration only)</td>
<td>P R</td>
<td>Contributes to cytotoxic stress</td>
<td>Most pronounced after direct exposure to high concentrations of free DHA and therefore has uncertain systemic relevance.</td>
</tr>
<tr>
<td>13</td>
<td>Chemosensitization</td>
<td>Drug sensitivity ↑ (model-dependent)<br>Oxidative injury ↑</td>
<td>Treatment toxicity ↔ or ↓ (context-dependent)</td>
<td>G</td>
<td>Adjunctive enhancement of treatment response</td>
<td>Supported by preclinical studies and small clinical investigations, especially in breast cancer. No validated DHA-based chemotherapy protocol or predictive biomarker is established.</td>
</tr>
<tr>
<td>14</td>
<td>Clinical Translation Constraint</td>
<td>Direct free-DHA exposure limited</td>
<td>Systemic nutritional effects predominate</td>
<td>G</td>
<td>Limits extrapolation from cell culture</td>
<td>Key constraints include esterification in plasma, slow tissue incorporation, variable formulation and oxidation, high in-vitro concentrations, tumor heterogeneity, small trials, mixed EPA-DHA products, and insufficient evidence for anticancer monotherapy.</td>
</tr>
</tbody>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br>
<br>
<p><b>Alzheimer’s disease relevance:</b> DHA is a major neuronal and synaptic membrane fatty acid and has strong biological relevance to brain aging, but supplementation is not an established treatment for Alzheimer’s disease. Proposed benefits include improved membrane organization, synaptic signaling, neurovascular function, inflammatory resolution, mitochondrial support, and modulation of amyloid processing. Human evidence is stage-dependent: observational associations and some mild-cognitive-impairment studies are favorable, whereas trials in established Alzheimer’s disease have generally not demonstrated meaningful reversal of cognitive decline.</p>
<p><b>Delivery and response constraints:</b> Brain uptake is regulated by circulating molecular form, blood-brain transport, hepatic lipid metabolism, baseline omega-3 status, and APOE genotype. Plasma DHA can increase substantially without a proportional rise in cerebrospinal-fluid or brain DHA. APOE ε4 carriers may have altered brain delivery and may require earlier intervention, higher exposure, or different carrier forms, but this remains under clinical investigation.</p>
<p><b>Clinical evidence status:</b> Mechanistically strong and clinically mixed. The most defensible classification is human RCT evidence with possible preventive or early-stage benefit, but insufficient evidence for treatment of established Alzheimer’s disease. Sustained dietary intake or supplementation before major neurodegeneration is more biologically plausible than late intervention.</p>
<br>
<h3>DHA Alzheimer’s Disease Axes</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Neuronal membrane and synaptic integrity</td>
<td>Membrane DHA ↑<br>Synaptic stability ↑</td>
<td>G</td>
<td>Supports neurotransmission and membrane organization</td>
<td>DHA is highly enriched in neuronal phospholipids. Deficiency can impair membrane fluidity, receptor function, vesicle dynamics, and dendritic-spine maintenance.</td>
</tr>
<tr>
<td>2</td>
<td>Neuroinflammatory resolution</td>
<td>Microglial inflammatory signaling ↓<br>Pro-resolving mediators ↑</td>
<td>R G</td>
<td>Promotes controlled resolution of inflammation</td>
<td>DHA-derived resolvins, protectins, and maresins may regulate microglial activation, cytokine production, phagocytosis, and tissue repair. Human mediator production is variable.</td>
</tr>
<tr>
<td>3</td>
<td>Brain delivery and APOE</td>
<td>CSF DHA ↑ (limited and genotype-dependent)</td>
<td>G</td>
<td>Determines effective neural exposure</td>
<td>Oral supplementation increases plasma DHA more readily than CSF DHA. APOE ε4 may reduce or alter brain delivery, making timing and formulation important.</td>
</tr>
<tr>
<td>4</td>
<td>Amyloid precursor processing</td>
<td>Aβ production or accumulation ↓ (preclinical)</td>
<td>G</td>
<td>May favor less amyloidogenic processing</td>
<td>Cell and animal evidence is stronger than clinical evidence. DHA has not consistently reduced cognitive decline in patients with established Alzheimer’s disease.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial and bioenergetic support</td>
<td>Mitochondrial membrane function ↑<br>ATP stability ↑</td>
<td>R G</td>
<td>Supports neuronal energy metabolism</td>
<td>Effects are generally protective at physiological incorporation levels but can vary with oxidative stress, aging, and membrane composition.</td>
</tr>
<tr>
<td>6</td>
<td>Oxidative stress balance</td>
<td>Antioxidant defenses ↑<br>Lipid oxidation ↑ if inadequately protected</td>
<td>R G</td>
<td>Produces a concentration-dependent redox tradeoff</td>
<td>DHA supports membrane function but is intrinsically oxidation-prone. Product oxidation and inadequate cellular antioxidant capacity may negate benefit.</td>
</tr>
<tr>
<td>7</td>
<td>BDNF and neuroplasticity</td>
<td>BDNF signaling ↑ (model-dependent)<br>Neuroplasticity ↑</td>
<td>G</td>
<td>Supports learning and synaptic adaptation</td>
<td>Well supported in experimental models but not established as a consistent mediator of cognitive improvement in Alzheimer’s trials.</td>
</tr>
<tr>
<td>8</td>
<td>Neurovascular and blood-brain barrier function</td>
<td>Endothelial function ↑<br>Barrier integrity ↑ (model-dependent)</td>
<td>G</td>
<td>May improve nutrient delivery and vascular resilience</td>
<td>Potentially relevant to mixed vascular and neurodegenerative cognitive impairment; direct clinical evidence remains limited.</td>
</tr>
<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td>Benefit ↓ after established neurodegeneration</td>
<td>G</td>
<td>Stage-dependent efficacy</td>
<td>Constraints include slow brain incorporation, APOE-dependent delivery, heterogeneous baseline intake, mixed formulations, insufficient trial duration, and irreversible neuronal loss before treatment begins.</td>
</tr>
</tbody>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br>